Edesa Biotech, Inc.

Analysis for Ticker: EDSA

Edesa Biotech Inc is a clinical stage biopharmaceutical company that claims to develop therapies for respiratory and skin conditions, but the internal numbers show it is actually a mechanism for moving shareholder cash into the pockets of the people running it. While the company has never earned a single dollar from distributing a product, the chief executive extracted 1.006.759$ in total pay during the 2025 fiscal year while the business lost 7,2$ million. To a child, this looks like a lemonade stand where the kids eat all the lemons and then ask their parents for more money to pay themselves for working. With an accumulated deficit of 65,9$ million, the company is trapped in a cycle of printing new shares out of thin air just to keep paying its own managers.